Theranos is in this casebook to mark where NAVETRA stops.
An execution-risk read prices a decision's environment. It does not verify whether the product works.

Most casebooks in this series make the same move: the data existed, the company reported it, the decision was never priced against it. Theranos breaks that move on purpose. The decisive fact at Theranos was not an unpriced environment a board could have read. It was a product that did not work, represented as one that did, and concealed until regulators and journalism forced it into view. No execution-risk read prices that. Saying so plainly is the entire point of including it.

Why this is a boundary piece, not a conversion

The other casebooks identify an endogenous capital decision whose exposure the company's own data already described, then show it was carried as narrative instead of priced as a number. Theranos has no such decision to convert. Forcing one would require the claim that an execution-environment read would have surfaced deliberately concealed scientific fraud. That claim is false, and making it would discredit every honest casebook beside it.

What is established, and what this casebook relies on

This piece rests only on the established public record. The SEC charged Theranos, its founder, and its former president, stating the company raised more than US$700 million through fraud; the founder settled the SEC matter and was later convicted on multiple counts at criminal trial; the former president was convicted on all counts brought to trial; regulators found conditions in the company's laboratory that posed immediate jeopardy to patient health and safety, and tens of thousands of results were voided. Those facts are not in dispute and are the only foundation used here.

NAVETRA was never engaged by Theranos. No Operating Profit at Risk figure is assigned, no domains are scored, and no claim is made that NAVETRA "would have" surfaced anything. The deciding failure was concealment of a product that did not work, and concealment is outside what an execution-risk read can see.

The distinction a board has to hold

The risk is that an execution-risk read gets mistaken for an assurance function, where a leadership team sees a clean environment read and infers the product is what it is claimed to be. Those are different questions, answered by different instruments, owned by different people. A board governing a highly technical product without independent technical validation capacity is not governing the product. It is governing management's description of it.

The one place the environment did matter, and its limit

There is a narrow, honest observation available, and it must be stated with its limit attached. An organisation holding a patient-facing product, with extreme secrecy, compartmentalised information, suppressed internal dissent, and a board lacking the technical competence to test the central claim, is an environment in which concealment is easier to sustain. An execution-environment read can describe that fragility in general terms.

What it cannot do, and what matters here, is convert "this environment makes concealment easier to sustain" into "the product does not work." Only independent validation does that. The boundary holds: NAVETRA can characterise an environment's fragility; it cannot verify whether a product performs, and it must not be sold or read as if it could.